Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology
Hormone receptor-positive/HER2-negative breast cancer evolves in response to therapy, demanding smarter, adaptive biomarker-based treatment strategies. We review emerging dynamic biomarkers to guide therapeutic decision-making, spanning tissue and liquid biopsies, metabolic imaging, and microbiome profiling, that capture tumor or host-related changes over time. By contrasting Academic and Industry approaches, we advocate for a cultural shift in clinical trial design and implementation, aiming to move from reactive to proactive Oncology.
Authors
- F. Schettini
- Daniele Generali (ORCID: https://orcid.org/0000-0003-2480-3855)
- Giuseppe Di Grazia (ORCID: https://orcid.org/0009-0001-6147-9655)
- Paolo Vigneri (ORCID: https://orcid.org/0000-0002-5943-6066)
- Rodrigo Sánchez-Bayona (ORCID: https://orcid.org/0000-0002-5255-6620)
- Casals-Pascual Climent
- A. Prat
- Tomás Pascual
- Javier Cortés
- Nadia Harbeck
Institutions
- University of Messina (IT)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- University of Trieste (IT)
- Breast Cancer Research Foundation (US)
- Instituto de Salud Carlos III (ES)
- University of Catania (IT)
- Hospital Universitario 12 De Octubre (ES)
- MedSIR (Spain) (ES)
- Centro de Investigación Biomédica en Red (ES)
- Hospital Clínic de Barcelona (ES)
- Cancer Clinic (US)
- Solti (ES)
- Oryzon Genomics (Spain) (ES)
- Barcelona Institute for Global Health (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Istituti Ospitalieri di Cremona (IT)
- Universitat de Barcelona (ES)
- Ludwig-Maximilians-Universität München (DE)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2026-01-28
- DOI
- https://doi.org/10.1038/s41523-026-00904-5
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Instituto de Salud Carlos III